secwatch / observer
8-K filed January 9, 2023, 6:59 PM ET ticker SGHT CIK 0001531177
earnings confidence high sentiment positive materiality 0.75

Sight Sciences reports preliminary Q4 2022 revenue ~$20.5M, up 40% YoY; CFO Selnick steps down, Rodberg interim

Sight Sciences, Inc.

2022-FY EPS reported -$1.80 revenue$71,331,000

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mack Hicks

Director
SGHT · Sight Sciences, Inc.
Effective
2023-01-05
Filed
January 9, 2023, 6:59 PM ET
Effective January 5, 2023, Mack Hicks stepped down as a Class II director and as a member of the Audit Committee of the Board
Departed

Jesse Selnick

Chief Financial Officer and Treasurer
SGHT · Sight Sciences, Inc.
Effective
2023-01-09
Successor
Jim Rodberg
Filed
January 9, 2023, 6:59 PM ET
Effective January 9, 2023, Jesse Selnick, the Company’s Chief Financial Officer and Treasurer, stepped down from his positions with the Company effective immediately.
Appointed (interim)

Jim Rodberg

Interim Chief Financial Officer and Treasurer
SGHT · Sight Sciences, Inc.
Effective
2023-01-09
Filed
January 9, 2023, 6:59 PM ET
Effective January 9, 2023, Jim Rodberg, the Company’s Vice President of Finance and Corporate Controller, was appointed by the Board of Directors of the Company (the “Board”) to serve as interim Chief Financial Officer and Treasurer until the appointment of Mr. Selnick’s successor.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sight Sciences, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $20.4 million to $20.6 million (Q4), $71.2 million to $71.4 million (full year).

Period
the fourth quarter and year ended December 31, 2022
Revenue
$20.4 million to $20.6 million (Q4), $71.2 million to $71.4 million (full year)
Result
preliminary results
Exact text from the filing
announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint. •
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Mack Hicks departed as Director at Sight Sciences, Inc..

Action
stepped down
Role
Director
Exact text from the filing
Effective January 5, 2023, Mack Hicks stepped down as a Class II director and as a member of the Audit Committee of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jesse Selnick departed as Chief Financial Officer and Treasurer at Sight Sciences, Inc..

Action
stepped down
Role
Chief Financial Officer and Treasurer
Exact text from the filing
Effective January 9, 2023, Jesse Selnick, the Company’s Chief Financial Officer and Treasurer, stepped down from his positions with the Company effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Jim Rodberg was appointed as Interim Chief Financial Officer and Treasurer at Sight Sciences, Inc..

Action
appointed
Role
Interim Chief Financial Officer and Treasurer
Exact text from the filing
Effective January 9, 2023, Jim Rodberg, the Company’s Vice President of Finance and Corporate Controller, was appointed by the Board of Directors of the Company (the “Board”) to serve as interim Chief Financial Officer and Treasurer until the appointment of Mr. Selnick’s successor.
View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-23-000514
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.